Ring Carbon Of Each Of The Two Five-membered Hetero Rings Is Bonded Directly To Chalcogen Or Nitrogen (e.g., Both Rings May Be Bonded To The Same Nitrogen Atom Or To Different Nitrogen Atoms, Etc.) Patents (Class 548/460)
  • Patent number: 10040922
    Abstract: The present disclosure relates to oxygen scavenging molecules, compositions comprising the molecules, and articles made from the compositions.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: August 7, 2018
    Assignee: PLASTIPAK PACKAGING, INC.
    Inventor: Girish N. Deshpande
  • Patent number: 9523004
    Abstract: A surface treatment composition comprising (i) an organosilicon compound having an alkoxysilane functional group at the end of a fluorocontaining polyether chain and (ii) fluorocontaining polyether compound s, wherein a content of the fluorocontaining polyether compounds in the surface treatment composition is less than 25 mol % based on the surface treatment composition.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: December 20, 2016
    Assignees: ESSILOR INTERNATIONAL, DOW CORNING CORPORATION, DAIKIN INDUSTRIES, LTD.
    Inventors: Gregory Hervieu, Pierre-Jean Calba, Don Lee Kleyer, Masayuki Hayashi, Peter Cheshire Hupfield, Tomohiro Yoshida, Yasuo Itami, Masahiko Maeda, Tetsuya Masutani
  • Publication number: 20140303207
    Abstract: The invention provides novel 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including but not limited to depression and anxiety.
    Type: Application
    Filed: April 3, 2013
    Publication date: October 9, 2014
    Applicant: NEUROVANCE, Inc.
    Inventors: Phil SKOLNICK, Zhengming Chen
  • Publication number: 20140288313
    Abstract: Disclosed are molecular and polymeric compounds having desirable properties as semiconducting materials. Such compounds can exhibit desirable electronic properties and possess processing advantages including solution-processability and/or good stability. Organic transistor and photovoltaic devices incorporating the present compounds as the active layer exhibit good device performance.
    Type: Application
    Filed: June 6, 2014
    Publication date: September 25, 2014
    Inventors: Tobin J. Marks, Antonio Facchetti, Pierre-Luc Boudreault, Hiroyuki Miyauchi
  • Publication number: 20140256954
    Abstract: The present disclosure relates to a compound comprising an aryloxy-phthalocyanine compound of group III metals, a method for preparing said compound and an article of manufacture made therefrom.
    Type: Application
    Filed: March 5, 2014
    Publication date: September 11, 2014
    Applicant: SAUDI BASIC INDUSTRIES CORPORATION
    Inventors: Timothy P. Bender, Benoit H. Lessard, Ahmed Abdelrahman, Amit Tevtia
  • Patent number: 8758880
    Abstract: Monomeric or polymeric compounds comprising at least one moiety of the formula (Ia) wherein X is CR, where R is H or a substituent as defined in claim 1, or is another ketopyrrole moiety e.g. of the formula (Ib) or (Ic) with this moiety and all other symbols are as defined in claim 1, show good solubility in organic solvents and excellent film-forming properties. In addition, high efficiency of energy conversion, excellent field-effect mobility, good on/off current ratios and/or excellent stability can be observed, when the polymers according to the invention are used in semiconductor devices or organic photovoltaic (PV) devices (solar cells).
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: June 24, 2014
    Assignee: BASF SE
    Inventors: Jean-Charles Flores, Ulrich Berens, Frank Bienewald, Hans Jürg Kirner, Mathieu G. R. Turbiez
  • Publication number: 20130331425
    Abstract: The invention relates to (among other things) polymer-sunitinib conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over sunitinib in unconjugated form.
    Type: Application
    Filed: December 23, 2011
    Publication date: December 12, 2013
    Applicant: NEKTAR THERAPEUTICS
    Inventors: Sean M. Culbertson, Antoni Kozlowski, Tony Drew Vinson
  • Publication number: 20130266752
    Abstract: The disclosure relates to oxygen scavenging molecules, compositions, methods of making the compositions, articles prepared from the compositions, and methods of making the articles. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: May 7, 2013
    Publication date: October 10, 2013
    Inventor: Girish N. Deshpande
  • Publication number: 20120289571
    Abstract: The present invention relates to releasable urea linker systems involving amine-containing chemical compounds and biologically active agents. In particular, the present invention relates to reversibly releasable linkers based on intramolecular cyclization-assisted releasable urea linkages to aromatic amine-containing compounds. The present invention also relates to polymeric conjugates of indolinone-based tyrosine kinase inhibitors.
    Type: Application
    Filed: December 30, 2010
    Publication date: November 15, 2012
    Applicant: ENZON PHARMACEUTICALS, INC.
    Inventors: Hong Zhao, Dechun Wu, Snehlata Tripathi, Jing Xia
  • Publication number: 20110251395
    Abstract: The invention relates to compounds of the structure of formula I and II: where X is selected from the group consisting of O, S and NH; Y, A and B are independently selected from the group consisting of N and CH; D, E and F are independently selected from the group consisting of CH, N, O and S; the symbol represents a single or a double bond; and R1, R2 and R3 are independently selected from the group consisting of H, electron withdrawing groups and electron releasing groups. In other embodiments, the compounds are used as oxygen scavengers and in barrier compositions and articles.
    Type: Application
    Filed: June 20, 2011
    Publication date: October 13, 2011
    Inventors: Girish Nilkanth Deshpande, Paul David Weipert, Michael W. Ensley
  • Patent number: 8008298
    Abstract: The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q1, R, and X are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: August 30, 2011
    Assignee: Roche Palo Alto
    Inventors: Joe Timothy Bamberg, Daisy Joe DuBois, Todd Richard Elworthy, Robert Than Hendricks, Johannes Cornelius Hermann, Alam Jahangir, Rama K. Kondru, Remy Lemoine, Yan Lou, Timothy D. Owens, David Bernard Smith, Michael Soth, Hanbiao Yang
  • Publication number: 20110117301
    Abstract: The disclosure relates to oxygen scavenging molecules, compositions, methods of making the compositions, articles prepared from the compositions, and methods of making the articles. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: November 12, 2010
    Publication date: May 19, 2011
    Inventor: Girish N. Deshpande
  • Patent number: 7781477
    Abstract: The invention relates to therapeutic use of compounds of general formula (I): in which X1, X2, X3, X4, X5, Z1, Z2, Z3, Z4 and Z5, R, Y and n are as defined herein.
    Type: Grant
    Filed: July 21, 2009
    Date of Patent: August 24, 2010
    Assignee: Sanofi-Aventis
    Inventors: Laurent Dubois, Yannick Evanno, Luc Even
  • Patent number: 7771695
    Abstract: Separation of carbon nanotubes or fullerenes according to diameter through non-covalent pi-pi interaction with molecular clips is provided. Molecular clips are prepared by Diels-Alder reaction of polyacenes with a variety of dienophiles. The pi-pi complexes of carbon nanotrubes with molecular clips are also used for selective placement of carbon nanotubes and fullerenes on substrates.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: August 10, 2010
    Assignee: International Business Machines Corporation
    Inventors: Ali Afzali-Ardakani, Cherie R. Kagan, Rudolf Tromp
  • Patent number: 7582671
    Abstract: The invention relates to therapeutic use of compounds of general formula (I): in which X1, X2, X3, X4, X5, Z1, Z2, Z3, Z4 and Z5, R, Y and n are as defined herein.
    Type: Grant
    Filed: April 25, 2008
    Date of Patent: September 1, 2009
    Assignee: Sanofi-Aventis
    Inventors: Laurent Dubois, Yannick Evanno, Luc Even
  • Patent number: 7572923
    Abstract: The present invention relates to an indirubin derivative having anticancer property by inhibiting cell proliferation as to human cancer cell line. More particularly, this invention provides the synthesis of indirubin derivative known as CDK(Cyclin-dependent kinase) inhibitor. Further, inhibition activity of proliferation as to human cancer cell line and apoptosis against induced-differentiation of said indirubin derivative are researched to develop a novel indirubin derivative having efficacious anticancer properties as to various human cell lines.
    Type: Grant
    Filed: January 26, 2005
    Date of Patent: August 11, 2009
    Assignee: Anygen Co., Ltd.
    Inventors: Yong-Chul Kim, Si Wouk Kim, Tae Sung Kim, Sang Kook Lee, Jae Il Kim, Jung-Hoon Yoon, Sang-Gun Ahn, Myoung Ju Moon
  • Publication number: 20090176840
    Abstract: This invention is directed to indolone derivatives which are antagonists or the GALR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: June 17, 2008
    Publication date: July 9, 2009
    Inventors: Michael Konkel, John M. Werzel, Jamie Talisman
  • Publication number: 20080277622
    Abstract: The invention relates to compounds of the structure of formula I and II: where X is selected from the group consisting of O, S and NH; Y, A and B are independently selected from the group consisting of N and CH; D, E and F are independently selected from the group consisting of CH, N, O and S; the symbol — represents a single or a double bond; and R1, R2 and R3 are independently selected from the group consisting of H, electron withdrawing groups and electron releasing groups. In other embodiments, the compounds are used as oxygen scavengers and in barrier compositions and articles.
    Type: Application
    Filed: May 9, 2008
    Publication date: November 13, 2008
    Inventors: Girish Nilkanth Deshpande, Paul David Weipert, Michael W. Ensley
  • Patent number: 7384969
    Abstract: The invention relates to compounds of general formula (I): in which X1, X2, X3, X4, X5, Z1, Z2, Z3, Z4 and Z5, R, Y and n are as defined herein. Also disclosed and claimed are the preparative methods and application of said compounds in therapeutics.
    Type: Grant
    Filed: January 18, 2007
    Date of Patent: June 10, 2008
    Assignee: Sanofi-Aventis
    Inventors: Laurent Dubois, Yannick Evanno, Luc Even
  • Patent number: 7241897
    Abstract: This invention provides for labeling reagents, labeled targets and processes for preparing labeling reagents. The labeling reagents can take the form of cyanine dyes, xanthene dyes, porphyrin dyes, coumarin dyes or composite dyes. These labeling reagents are useful for labeling probes or targets, including nucleic acids and proteins. These reagents can be usefully applied to protein and nucleic acid probe based assays. They are also applicable to real-time detection processes.
    Type: Grant
    Filed: January 21, 2004
    Date of Patent: July 10, 2007
    Assignee: Enzo Life Sciences, Inc.
    Inventors: Jannis G. Stavrianopoulos, Elazar Rabbam
  • Patent number: 7157577
    Abstract: The present invention relates to 5-sulfonamido substituted indolinones that modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
    Type: Grant
    Filed: March 8, 2004
    Date of Patent: January 2, 2007
    Assignee: Sugen Inc.
    Inventors: Peng Cho Tang, Congxin Liang, Todd Miller, Kenneth E. Lipson
  • Patent number: 6750240
    Abstract: The present invention relates to novel synthetic methods for the preparation of indolylquinones. The methods of the present invention are directed to synthetic reactions involving indoles and halo-quinones in solvent and in the presence of a metal carbonate. The invention also relates to bis- and mono-indolylquinones of high purity and pharmaceutical compositions containing the same.
    Type: Grant
    Filed: May 3, 2000
    Date of Patent: June 15, 2004
    Assignee: Sugen, Inc.
    Inventors: Peng C. Tang, G. Davis Harris
  • Patent number: 6734185
    Abstract: Corticotropin releasing factor (CRF) antagonists of Formula (II) and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
    Type: Grant
    Filed: June 9, 2003
    Date of Patent: May 11, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventor: Rajagopal Bakthavatchalam
  • Patent number: 6630476
    Abstract: Corticotropin releasing factor (CRF) antagonists of Formula (I) or (II) and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: October 7, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventor: Rajagopal Bakthavatchalam
  • Patent number: 6448412
    Abstract: The invention is directed to multiply-substituted fullerene derivatives of novel configurations, and methods for their preparation and use. The methods involve the combinatorial synthesis of a library of fullerene derivatives and comprises the steps of forming a mixture of fullerene derivatives by reacting the Cn fullerene with two or more reactive precursor compounds, and removing the unreacted compounds to yield the fullerene derivatives having the desired activity. Methods for the identification and screening of a combinatorial library of fullerenes by 3He-nuclear magnetic resonance and electrospray mass spectrometry to define members with the optimal desired activity are also provided.
    Type: Grant
    Filed: October 30, 2000
    Date of Patent: September 10, 2002
    Assignee: Sphere Biosystems, Inc.
    Inventors: Randall B. Murphy, Stephen R. Wilson, Quing Lu
  • Patent number: 6399785
    Abstract: The invention is directed to multiply-substituted fullerene derivatives of novel configurations, and methods for their preparation and use. The methods involve the combinatorial synthesis of a library of fullerene derivatives and comprises the steps of forming a mixture of fullerene derivatives by reacting the Cn fullerene with two or more reactive precursor compounds, and removing the unreacted compounds to yield the fullerene derivatives having the desired activity. Methods for the identification and screening of a combinatorial library of fullerenes by 3He-nuclear magnetic resonance and electrospray mass spectrometry to define members with the optimal desired activity are also provided.
    Type: Grant
    Filed: October 30, 2000
    Date of Patent: June 4, 2002
    Assignee: C-Sixty, Inc.
    Inventors: Randall B. Murphy, Stephen R. Wilson, Quing Lu
  • Patent number: 6376529
    Abstract: The present invention relates to a class of indolylquinone compounds that inhibit GRB-2 adaptor protein function, pharmaceutical compositions comprising these compounds, and methods for ameliorating the symptoms of cell proliferative disorders associated with GRB-2 adaptor protein function using these compounds. The present invention further relates to methods for treating insulin-related disorders, such as diabetes, insulin resistance, insulin deficiency and insulin allergy, and for ameliorating the symptoms of insulin-related disorders, using certain indolylquinone compounds and pharmaceutical compositions thereof. The present invention also relates to novel synthetic methods for the preparation of mono- and bis-indolylquinone compounds.
    Type: Grant
    Filed: September 24, 1999
    Date of Patent: April 23, 2002
    Inventors: Peng Cho Tang, Gerald McMahon, G. Davis Harris, Jr., Ken Lipson
  • Publication number: 20020022626
    Abstract: The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting protein kinase signal transduction. Such compounds are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis and restenosis and metabolic diseases such as diabetes. The present invention features indolinone compounds that potently inhibit protein kinases and related products and methods. Inhibitors specific to the FLK protein kinase can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone, in particular at the 1′ position of the indole ring. Indolinone compounds that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano-b-pyrrol moiety.
    Type: Application
    Filed: July 13, 2000
    Publication date: February 21, 2002
    Inventors: Peng Cho Tang, LI Sun, Gerald McMahon, Klaus Peter Hirth, Laura Kay Shawver
  • Publication number: 20020015938
    Abstract: The invention relates to a method of simultaneous high-throughput preformulation quantification of potential drug candidates, where an aliquot of a mixture of solutions containing different compounds is injected into a high pressure liquid chromatograph. The concentration of each compound can be determined by high pressure liquid chromatographic analysis, and correlated to a physico-chemical property of the compound.
    Type: Application
    Filed: October 29, 1998
    Publication date: February 7, 2002
    Inventor: NARMADA SHENOY
  • Patent number: 6274728
    Abstract: Compounds of formula A(B)x  (I), wherein x is an integer from 1 to 8, A is the radical of a chromophore of the quinacridone, anthraquinone, perylene, indigo, quinophthalone, indanthrone, isoindolinone, isoindoline, dioxazine, azo, phthalocyanine or diketopyrrolopyrrole series that is bonded to x groups B via one or more hetero atoms, those hetero atoms being selected from the group consisting of N, O and S and forming part of the radical A, each group B independently of any other(s) is hydrogen or a group of the formula  at least one group B being a group of the formula The compounds according to the invention are used in high-molecular-weight organic materials, thermo-, photo- or chemo-sensitive recording materials, light-sensitive negative or positive resist compositions, ink compositions for ink-jet printing and color tapes for thermal transfer printing.
    Type: Grant
    Filed: December 16, 1999
    Date of Patent: August 14, 2001
    Assignee: Ciba Specialty Chemicals Corp.
    Inventors: Véronique Hall-Goulle, Aline Bize
  • Patent number: 6187809
    Abstract: Compounds having a &bgr;-3 adrenaline receptor agonist and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc., represented by a general formula (I) and salts thereof, and a process for producing these, and their intermediates, wherein R represents hydrogen or methyl; R1 represents hydrogen, halogen, hydroxy, benzyloxy, amino, or hydroxymethyl; R2 represents hydrogen, hydroxymethyl, NHR3, SO2NR4R4, or nitro; R6 represents hydrogen or lower alkyl; and X represents nitrogen, R9 represents hydrogen, one of R7 and R8 represent hydrogen, and the other thereof represents hydrogen, amino, acetylamino, or hydroxy.
    Type: Grant
    Filed: December 28, 1999
    Date of Patent: February 13, 2001
    Assignee: Asahi Kasei Kogyo Kabushiki Kaisha
    Inventors: Shiro Miyoshi, Kohei Ogawa
  • Patent number: 6162926
    Abstract: The invention is directed to multiply-substituted fullerene derivatives of novel configurations, and methods for their preparation and use. The methods involve the combinatorial synthesis of a library of fullerene derivatives and comprises the steps of forming a mixture of fullerene derivatives by reacting the C.sub.n fullerene with two or more reactive precursor compounds, and removing the unreacted compounds to yield the fullerene derivatives having the desired activity. Methods for the identification and screening of a combinatorial library of fullerenes by .sup.3 He-nuclear magnetic resonance and electrospray mass spectrometry to define members with the optimal desired activity are also provided.
    Type: Grant
    Filed: November 13, 1997
    Date of Patent: December 19, 2000
    Assignee: Sphere Biosystems, Inc.
    Inventors: Randall B. Murphy, Stephen R. Wilson, Quing Lu
  • Patent number: 6147106
    Abstract: The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting protein kinase signal transduction. Such compounds are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis and restenosis and metabolic diseases such as diabetes. The present invention features indolinone compounds that potently inhibit protein kinases and related products and methods. Inhibitors specific to the FLK protein kinase can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone, in particular at the 1' position of the indole ring. Indolinone compounds that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano-b-pyrrol moiety.
    Type: Grant
    Filed: August 20, 1997
    Date of Patent: November 14, 2000
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, Klaus Peter Hirth, Laura Kay Shawver
  • Patent number: 6130238
    Abstract: The present invention relates to novel 3-(cyclohexanoheteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: June 19, 1998
    Date of Patent: October 10, 2000
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Patent number: 5919469
    Abstract: Products derived from 2-imino-2,3-dihydro-1H-indoles resulting from the oxidative polymerization of at least one compound of formula (I) or (II) below: ##STR1## in which: R.sub.1, R.sub.2 and R.sub.3 denote hydrogen, alkyl, carboxyl, alkoxycarbonyl, monohydroxyalkyl, polyhydroxyalkyl, alkoxyalkyl, monoalkylaminoalkyl or dialkylaminoalkyl; R'.sub.3 and R.sub.4 denote alkyl, carboxyl, alkoxycarbonyl, monohydroxyalkyl, polyhydroxyalkyl, alkoxyalkyl, monoalkylaminoalkyl or dialkylaminoalkyl;R.sub.5 denotes hydrogen, alkyl, monohydroxyalkyl, polyhydroxyalkyl, alkoxyalkyl, monoalkylaminoalkyl or dialkylaminoalkyl;and to the addition salts thereof with an acid, as well as to their uses in cosmetics for making up the exoskeleton and/or the skin.
    Type: Grant
    Filed: August 22, 1997
    Date of Patent: July 6, 1999
    Assignee: L'Oreal
    Inventor: Alain Lagrange
  • Patent number: 5886160
    Abstract: Compounds of formulaA(B).sub.x, (I),wherein x is an integer from 1 to 4,A is the radical of a chromophore of the quinacridone, anthraquinone, perylene, indigo, quinophthalone, isoindolinone, isoindoline, dioxazine, phthalocyanine or azo series, which radical contains x N-atoms attached to B, preferably with at least one directly adjacent or conjugated carbonyl group,B is a group of formula ##STR1## and, if x is 2, 3 or 4, may also be one, two or three hydrogen atoms. The symbols Q, R.sub.1, R.sub.2, R.sub.3, R.sub.4, X, Y, Z, m and n, are as defined in claim 1.These carbamate group-containing soluble chromophores are distinguished by outstanding solid state fluorescence in the UV range as well as the by ease with which they can be converted to the corresponding pigments in the substrate in which they are incorporated.
    Type: Grant
    Filed: June 12, 1998
    Date of Patent: March 23, 1999
    Assignee: Ciba Specialty Chemicals Corporation
    Inventors: Zhimin Hao, John S. Zambounis, Abul Iqbal
  • Patent number: 5786488
    Abstract: The present invention relates to novel synthetic methods for the preparation of indolylquinones. The methods of the present invention are directed to synthetic reactions involving indoles and halo-quinones in solvent and in the presence of a metal carbonate. The invention also relates to bis- and mono-indolylquinones of high purity and pharmaceutical compositions containing the same.
    Type: Grant
    Filed: November 5, 1997
    Date of Patent: July 28, 1998
    Assignee: Sugen, Inc.
    Inventors: Peng C. Tang, G. Davis Harris
  • Patent number: 5597916
    Abstract: Compounds of Formula I have been shown to enhance the release of the neurotransmitter acetylcholine, and thus may be useful as chemical intermediates and as pharmacological agents in the treatment of diseases of man, such as in Alzheimer's Disease and other conditions involving learning and cognition, where subnormal levels of this neurochemical are found.
    Type: Grant
    Filed: February 21, 1996
    Date of Patent: January 28, 1997
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventor: Christopher A. Teleha
  • Patent number: 5583234
    Abstract: An indoline product obtained by oxidizing at least one compound of formula (I), ##STR1## wherein R.sub.1 and R.sub.3 independently represent a hydrogen atom or a C.sub.1-4 alkyl grouping; R.sub.2 represents a hydrogen atom, a C.sub.1-4 alkyl grouping, a carboxyl grouping or C.sub.1-4 alkoxycarbonyl; R.sub.4 is a hydrogen atom, a C.sub.1-4 alkyl grouping, hydroxyl, C.sub.1-4 alkoxy, C.sub.1-10 amino or alkylamino, or halogen; R.sub.5 is a hydrogen atom, a hydroxyl grouping, C.sub.1-4 alkoxy or amino; with the proviso that at least one of the radicals R.sub.4 or R.sub.5 is a hydroxyl, alkoxy or amino grouping, and that when R.sub.5 is an amino grouping, R.sub.4 is not an alkylamino radical; R.sub.4 and R.sub.5 may also form a C.sub.1-2 alkylenedioxy ring and are in positions 5 and 6; and corresponding salts thereof. Said product may be used in cosmetics as make-up for the hair, eyebrows, eyelashes, nails, etc., and/or skin.
    Type: Grant
    Filed: December 29, 1993
    Date of Patent: December 10, 1996
    Assignee: L'Oreal
    Inventors: Alain Lagrange, Herv e Andrean, Alex Junino
  • Patent number: 5556874
    Abstract: 2-Thioindoles (2-selenoindoles) and analogous 2-indolinethione (2-indolineselenone) and polysulfide (selenide) compounds, salts thereof, methods of production, intermediates in their production, pharmaceutical compositions containing said compounds, and methods for inhibiting protein kinase dependent disease in a mammal or treating aberrant cell growth in a mammal, using said compositions, are disclosed.
    Type: Grant
    Filed: May 10, 1995
    Date of Patent: September 17, 1996
    Assignee: Warner Lambert Company
    Inventors: Ellen M. Dobrusin, Howard D. H. Showalter, William A. Denny, Brian D. Palmer, Gordon W. Rewcastle, Moana Tercel, Andrew M. Thompson
  • Patent number: 5478859
    Abstract: The present patent application discloses compounds having the formula ##STR1## or a pharmaceutically acceptable salt thereof wherein R.sup.21 and R.sup.22 each independently are alkyl; andR.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.11, R.sup.12, R.sup.13, and R.sup.14 each independently are hydrogen, halogen, CF.sub.3, CN, or NO.sub.2.The compounds are useful as in vivo active glutamate antagonists.
    Type: Grant
    Filed: June 13, 1994
    Date of Patent: December 26, 1995
    Assignee: NeuroSearch A/S
    Inventors: Frank Watjen, Jorgen Drejer, Leif H. Jensen
  • Patent number: 5464861
    Abstract: 2-Thioindoles (2-selenoindoles) and analogous 2-indolinethione (2-indolineselenone) and polysulfide (selenide) compounds, salts thereof, methods of production, intermediates in their production, pharmaceutical compositions containing said compounds, and methods for inhibiting protein kinase dependent disease in a mammal or treating aberrant cell growth in a mammal, using said compositions, are disclosed.
    Type: Grant
    Filed: August 9, 1993
    Date of Patent: November 7, 1995
    Assignee: Warner-Lambert
    Inventors: Ellen M. Dobrusin, Howard D. H. Showalter, William A. Denny, Brian D. Palmer, Gordon W. Rewcastle, Moana Tercel, Andrew M. Thompson
  • Patent number: 5399562
    Abstract: This invention relates to compounds of the formula: ##STR1## which are useful as 5-HT.sub.4 agonists or antagonists and 5-HT.sub.3 antagonists.
    Type: Grant
    Filed: February 4, 1994
    Date of Patent: March 21, 1995
    Assignee: G. D. Searle & Co.
    Inventors: Daniel P. Becker, Daniel L. Flynn, Clara I. Villamil
  • Patent number: 5252536
    Abstract: Substituted indolinone compounds which are effective in the control of undesirable plant species are described. Also described are a method for the herbicidal use of the compounds and a method for their preparation.
    Type: Grant
    Filed: December 31, 1991
    Date of Patent: October 12, 1993
    Assignee: American Cyanamid Company
    Inventors: Michael E. Condon, Gary M. Karp
  • Patent number: 5110986
    Abstract: This application relates to a process for preparing a N-t-alkyl-1,2-diacylhydrazine by reacting a 1,3,4-oxadiazole with a tertiary alkyl cation precursor in the presence of a strong acid catalyst. Preferably, the 1,3,4-oxadiazole is a 2,5-disubstituted-1,3,4-oxadiazole and more preferably a 2,5-diaryl-1,3,4-oxadiazole. The strong acid catalyst is preferably a sulfur containing acid and more preferably sulfuric acid.
    Type: Grant
    Filed: April 26, 1988
    Date of Patent: May 5, 1992
    Assignee: Rohm and Haas Company
    Inventor: Martha J. Kelly
  • Patent number: 5047417
    Abstract: A butenoic or propenoic acid derivative having the following formula in which G is an aryl or a heterocyclic ring, R11 and R12 are hydrogen or an alkyl, X is sulfur or oxygen, R2 and R3 are hydrogen, an substituent such as an alkyl and J is pyridyl or phenyl having substituents and a heterocyclic ring may be formed between R2, R3 and J is provided here and is useful in the pharmacological field.
    Type: Grant
    Filed: May 19, 1989
    Date of Patent: September 10, 1991
    Assignee: Eisai Co. Ltd.
    Inventors: Norio Minami, Fumihiro Ozaki, Keiji Ishibashi, Yasuhiro Kabasawa, Megumi Ikemori, Toshiaki Ogawa, Takanori Kawamura
  • Patent number: 5030734
    Abstract: Solid solutions consisting of at least two different compounds of the formula I ##STR1## in which A is one of the groups ##STR2## in which R and R.sup.1 independently of one another are hydrogen, halogen, C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkoxy, X is halogen, Y and Z independently of one another are halogen, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkylmercapto, C.sub.5 -C.sub.6 cycloalkoxy, phenoxy which is unsubstituted or substituted by halogen or C.sub.1 -C.sub.4 alkyl, wherein the compounds of the formula I which form the solid solutions differ in at least one of the substituents X, Y or Z and/or in the group A and the X-ray diffraction patterns of the solid solutions differ from the sum of the X-ray diffraction patterns of the individual components.This type of solid solution is highly suitable for use as pigments for the dyeing of high-molecular-weight organic material.
    Type: Grant
    Filed: October 17, 1988
    Date of Patent: July 9, 1991
    Assignee: Ciba-Geigy Corporation
    Inventor: Fridolin Babler
  • Patent number: 4983630
    Abstract: There are provided new 2,2-difluorocyclopropylethane derivatives of general formula I ##STR1## in which A, B and R.sup.1-5 have the meanings given in the description and processes for their preparation. The compounds of the invention can be used as pesticides, especially against insects and mites.
    Type: Grant
    Filed: November 28, 1988
    Date of Patent: January 8, 1991
    Assignee: Schering Aktiengesellschaft
    Inventors: Peter Wegner, Hartmut Joppien, Gunter Homberger, Arnim Kohn
  • Patent number: 4914213
    Abstract: A 5-hydroxy-N-substituted indole derivative and the process for producing the indole derivative are described the indole derivative is produced by a process comprising reacting a phenol derivative having an unsaturated double bond in the m-position with a diazonium salt.
    Type: Grant
    Filed: February 4, 1987
    Date of Patent: April 3, 1990
    Assignee: Fuji Photo Film Co., Ltd.
    Inventor: Masato Satomura
  • Patent number: 4892899
    Abstract: Composition of matter containing(a) a compound of the formula I ##STR1## in which A is one of the groups of the formulae ##STR2## in which B is --O--, --S--, --SO.sub.2 --, --N.dbd.N--, --CH.sub.2 --, --CH.dbd.CH--, ##STR3## --CONH--, --NHCONH--, or --CONHNHCO--, Q is --O-- or --NH-- and Z is --O-- or --S-- and R and R' are independently of each other hydrogen, halogen, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -alkoxy or phenoxy, and(b) a compound of the formula II ##STR4## in which A' is as defined above for A, D is hydrogen, amino or a group of the formula III ##STR5## E is --O-- or --S--, T.sub.1, T.sub.2 and T.sub.3 independently of one another are chlorine or a group --ET', T' is a group of the formulae ##STR6## X.sup..sym. is H.sup..sym. or a group of the formulae M.sup.n.sym. /n or N.sup..beta. (R.sub.1)(R.sub.2)(R.sub.3)(R.sub.4), Mhu n.sym. is an n-valent metal cation, n is 1, 2 or 3, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently of one another hydrogen, C.sub.1 -C.sub.18 -alkyl, C.sub.
    Type: Grant
    Filed: December 8, 1987
    Date of Patent: January 9, 1990
    Assignee: Ciba-Geigy Corporation
    Inventors: Edward E. Jaffe, Jost von der Crone, Bernhard Medinger